MEF2D and acute lymphoblastic leukemia: In a study of relapsed ALL, MEF2D-BCL9 fusion was found in 4 of 59 relapsed or refractory ALL patients who had older age (10 to 13 years), very early relapse (8 to 15 months from diagnosis), and very poor outcome (0% survival) [53].